FR12C0048I2 - QUINAZOLINE DERIVATIVES USED AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS - Google Patents
QUINAZOLINE DERIVATIVES USED AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORSInfo
- Publication number
- FR12C0048I2 FR12C0048I2 FR12C0048C FR12C0048C FR12C0048I2 FR 12C0048 I2 FR12C0048 I2 FR 12C0048I2 FR 12C0048 C FR12C0048 C FR 12C0048C FR 12C0048 C FR12C0048 C FR 12C0048C FR 12C0048 I2 FR12C0048 I2 FR 12C0048I2
- Authority
- FR
- France
- Prior art keywords
- vegf
- inhibitors
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99402759 | 1999-11-05 | ||
EP99402877 | 1999-11-19 | ||
PCT/GB2000/004181 WO2001032651A1 (en) | 1999-11-05 | 2000-11-01 | Quinazoline derivatives as vegf inhibitors |
EP00974667A EP1244647B1 (en) | 1999-11-05 | 2000-11-01 | Quinazoline derivatives as vegf inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FR12C0048I1 FR12C0048I1 (en) | 2012-09-14 |
FR12C0048I2 true FR12C0048I2 (en) | 2013-08-16 |
Family
ID=26153696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR12C0048C Active FR12C0048I2 (en) | 1999-11-05 | 2012-08-09 | QUINAZOLINE DERIVATIVES USED AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS |
Country Status (36)
Country | Link |
---|---|
US (9) | US7173038B1 (en) |
EP (2) | EP1676845B1 (en) |
JP (1) | JP3522727B2 (en) |
KR (3) | KR100881104B1 (en) |
CN (2) | CN101219145A (en) |
AR (1) | AR033499A1 (en) |
AT (2) | ATE398120T1 (en) |
AU (1) | AU769222B2 (en) |
BE (1) | BE2012C036I2 (en) |
BG (1) | BG65861B1 (en) |
BR (2) | BRPI0015203B8 (en) |
CA (1) | CA2389767C (en) |
CY (3) | CY1106166T1 (en) |
CZ (1) | CZ301689B6 (en) |
DE (2) | DE60039206D1 (en) |
DK (2) | DK1244647T3 (en) |
EE (1) | EE05330B1 (en) |
ES (2) | ES2306306T3 (en) |
FR (1) | FR12C0048I2 (en) |
HK (2) | HK1049664B (en) |
HU (1) | HU229414B1 (en) |
IL (2) | IL149034A0 (en) |
IS (2) | IS2284B (en) |
LU (1) | LU92057I2 (en) |
MX (1) | MXPA02004366A (en) |
NO (2) | NO322298B1 (en) |
NZ (1) | NZ518028A (en) |
PL (1) | PL203782B1 (en) |
PT (2) | PT1244647E (en) |
RU (1) | RU2291868C2 (en) |
SI (2) | SI1244647T1 (en) |
SK (1) | SK287401B6 (en) |
TW (1) | TWI287540B (en) |
UA (1) | UA72946C2 (en) |
WO (1) | WO2001032651A1 (en) |
ZA (1) | ZA200202775B (en) |
Families Citing this family (217)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
MXPA02004366A (en) | 1999-11-05 | 2002-11-07 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors. |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
DE60310383T2 (en) * | 2002-01-29 | 2007-09-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | PREVENTION OF TISSUE ADHESION |
EP1474420B1 (en) | 2002-02-01 | 2012-03-14 | AstraZeneca AB | Quinazoline compounds |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
KR20050056190A (en) * | 2002-08-09 | 2005-06-14 | 아스트라제네카 아베 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
DE10237423A1 (en) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
SI1562955T1 (en) * | 2002-11-04 | 2008-06-30 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
DK1592423T3 (en) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU and / or CPT-11 |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
GB0316176D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
MXPA06000114A (en) * | 2003-07-10 | 2006-04-27 | Astrazeneca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability. |
TWI476206B (en) | 2003-07-18 | 2015-03-11 | Amgen Inc | Specific binding agents to hepatocyte growth factor |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
SI1667991T1 (en) * | 2003-09-16 | 2008-10-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
EP1670786A1 (en) * | 2003-09-25 | 2006-06-21 | Astrazeneca AB | Quinazoline derivatives |
GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
WO2005075439A1 (en) | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
GB0421438D0 (en) * | 2004-09-27 | 2004-10-27 | Astrazeneca Ab | Combination therapy |
GB0411378D0 (en) | 2004-05-21 | 2004-06-23 | Astrazeneca Ab | Pharmaceutical compositions |
WO2006002422A2 (en) * | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
BRPI0516052A (en) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | use of zd6474 or a pharmaceutically acceptable salt thereof and imatinib, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
CN1854130B (en) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | Chinazoline derivative, its production, medicinal composition and use |
ES2333182T3 (en) | 2005-05-18 | 2010-02-17 | Array Biopharma, Inc. | DERIVATIVES OF 4- (PHENYLAMINE) -6-OXO-1,6-DIHIDROPIRIDAZINA-3-CARBOXAMIDE AS MEK INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. |
GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
AU2011203358B2 (en) * | 2005-09-30 | 2013-05-30 | Genzyme Corporation | Chemical process |
GB0519878D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical compound |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
ATE489380T1 (en) | 2006-02-10 | 2010-12-15 | Amgen Inc | HYDRATE FORMS OF AMG706 |
AR060358A1 (en) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | QUINAZOLINS FOR THE INHIBITION OF PDK 1 |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
KR20080110912A (en) | 2006-04-19 | 2008-12-19 | 노파르티스 아게 | Indazole compounds and methods for inhibition of cdc7 |
PE20080403A1 (en) | 2006-07-14 | 2008-04-25 | Amgen Inc | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
US8044049B2 (en) | 2006-08-04 | 2011-10-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
SI2057156T1 (en) | 2006-08-23 | 2017-06-30 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
JP5528806B2 (en) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | Compound drug |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008046242A1 (en) * | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | The novel quinazoline derivatives,preparation methods and uses thereof |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
US7759344B2 (en) | 2007-01-09 | 2010-07-20 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
JP5377332B2 (en) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bicyclic heterocycles, drugs containing these compounds, their use and their preparation |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
AR065784A1 (en) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES. |
US8914063B2 (en) | 2007-05-15 | 2014-12-16 | Lg Electronics Inc. | Mobile terminal equipped with mode setting key and method of controlling the mobile terminal |
CL2008001626A1 (en) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer. |
EA201591355A1 (en) | 2007-08-21 | 2016-04-29 | Амген Инк. | ANTIGEN-BINDING PROTEINS, CONNECTING c-fms of the PERSON |
WO2009025358A1 (en) | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
PE20131210A1 (en) | 2007-12-19 | 2013-10-31 | Genentech Inc | 5-ANILINOIMIDAZOPYRIDINE DERIVATIVES AS MEK INHIBITORS |
CA2710122A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
CA2708176A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
WO2009094210A1 (en) * | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Vandetanib derivatives |
PL2245026T3 (en) | 2008-02-07 | 2013-01-31 | Boehringer Ingelheim Int | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
CA2715181A1 (en) * | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
ES2444128T3 (en) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | New SAL-554 |
US20110200612A1 (en) | 2008-06-30 | 2011-08-18 | Michael Schuster | Treatment of eye diseases and excessive neovascularization using combined therapy |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JO3101B1 (en) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | Benzothiazole derivatives as anticancer agents |
US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
JP2012513194A (en) | 2008-12-23 | 2012-06-14 | アストラゼネカ アクチボラグ | Targeted binding agents directed to α5β1 and uses thereof |
EP3100745B1 (en) | 2009-02-05 | 2018-04-18 | Immunogen, Inc. | Novel benzodiazepine derivatives |
WO2010103094A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
CA2771675A1 (en) | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
CN102666545B (en) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor |
CN102070608A (en) * | 2009-11-19 | 2011-05-25 | 天津药物研究院 | 4-substituted phenylamino-7-substituted alkoxy-quinazoline derivant and preparation method and application thereof |
EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
JP2013512859A (en) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | Imidazoquinoline acting through a toll-like receptor (TLR) |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
ES2535116T3 (en) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Urea derivatives with morpholino as mtor inhibitors |
JP2013525392A (en) | 2010-04-30 | 2013-06-20 | セルゾーム リミティッド | Pyrazole compounds as JAK inhibitors |
SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl Compounds for Use as ATR Inhibitors |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
AR082418A1 (en) | 2010-08-02 | 2012-12-05 | Novartis Ag | CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO |
JP2013534233A (en) | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | Heterocyclylpyrazolopyrimidine analogs as selective JAK inhibitors |
SG10201408229WA (en) | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
CA2815330A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
CN102532103B (en) * | 2010-12-20 | 2014-07-09 | 天津药物研究院 | Quinazolinyl aryl urea derivatives and preparation method and application thereof |
ES2611885T3 (en) | 2011-01-31 | 2017-05-11 | Novartis Ag | Novel Heterocyclic Derivatives |
MY183977A (en) | 2011-02-15 | 2021-03-17 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
JP5937111B2 (en) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited | FAK inhibitor |
ES2620521T3 (en) | 2011-03-23 | 2017-06-28 | Amgen Inc. | Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3 |
US20140163023A1 (en) | 2011-04-04 | 2014-06-12 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
AU2012288892B2 (en) | 2011-07-28 | 2016-04-21 | Cellzome Limited | Heterocyclyl pyrimidine analogues as JAK inhibitors |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
EP2760863A1 (en) | 2011-09-20 | 2014-08-06 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
US9242993B2 (en) | 2011-10-07 | 2016-01-26 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
PL2771342T3 (en) | 2011-10-28 | 2016-11-30 | Purine derivatives and their use in the treatment of disease | |
CN104169272A (en) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
SG10201608469RA (en) | 2012-05-16 | 2016-11-29 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
ES2611788T3 (en) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use |
CA2882158A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
BR112015004022B1 (en) | 2012-08-31 | 2023-04-25 | Sutro Biopharma, Inc | MODIFIED AMINO ACIDS COMPRISING AN AZID GROUP |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
WO2014074517A1 (en) * | 2012-11-08 | 2014-05-15 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
KR20150118159A (en) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | Methods of treating cancer and preventing drug resistance |
JP6494533B2 (en) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | Complexes comprising maytansinoids as cell binding agents and cytotoxic agents |
WO2014134486A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
CN105246511A (en) | 2013-03-06 | 2016-01-13 | 豪夫迈·罗氏有限公司 | Methods of treating and preventing cancer drug resistance |
EP2968565A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
JP2016520528A (en) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | Cancer treatment and anticancer drug resistance prevention method |
AR095443A1 (en) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | HEREROCICLES CONDENSED WITH ACTION ON ATR |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP3039424B1 (en) | 2013-08-28 | 2020-07-29 | Crown Bioscience, Inc. (Taicang) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
CN103483276B (en) * | 2013-09-22 | 2018-04-17 | 南京恒道医药科技有限公司 | Preparation method of vandetanib impurity |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
CN105979947A (en) | 2013-12-06 | 2016-09-28 | 诺华股份有限公司 | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CN106317022A (en) * | 2015-06-25 | 2017-01-11 | 中美华世通生物医药科技(武汉)有限公司 | Preparation method and use of compound |
EP3370719A1 (en) | 2015-11-02 | 2018-09-12 | Novartis AG | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
CN105254614B (en) * | 2015-11-16 | 2017-08-15 | 山东罗欣药业集团股份有限公司 | A kind of synthetic method of ZD6474 compound |
SG11201806419RA (en) | 2016-01-27 | 2018-08-30 | Sutro Biopharma Inc | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
CN109072241A (en) | 2016-02-08 | 2018-12-21 | 维特里萨医疗公司 | With the improved composition of vitreous half-life and application thereof |
CN106317040A (en) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | Benzo quinazoline tyrosine kinase inhibitor containing thiophene-sulfonamide structure, preparation method and application |
CN106317039A (en) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | Ethoxy benzo quinazoline type tyrosine kinase inhibitor containing thiophenesulfonyl structure, preparation method and application |
CN106349231A (en) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | Benzoquinazoline tyrosine kinase inhibitor containing halothiophene sulfonamide structure |
CN106349230A (en) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | Benzo-quinazoline tyrosine kinase inhibitor with nitrothiophene sulfamide structure and application |
CN106279135A (en) * | 2016-08-09 | 2017-01-04 | 浙江医药高等专科学校 | A kind of Benzoquinazole class tyrosine kinase inhibitor of thiophenesulfonyl amine structure |
CN106478598B (en) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | A kind of Vande Thani hydrate crystal and preparation method thereof |
CN106397401B (en) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | A kind of crystalline compounds of anticancer drug and preparation method thereof |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
US10287253B2 (en) | 2016-12-05 | 2019-05-14 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
LT3558955T (en) | 2016-12-22 | 2021-11-10 | Amgen Inc. | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
TWI731264B (en) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Inhibitors of kras g12c and methods of using the same |
US20200353076A1 (en) | 2017-09-18 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
JP7266043B2 (en) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C inhibitors and methods of using them |
MX2020011582A (en) | 2018-05-04 | 2020-11-24 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
JP7361720B2 (en) | 2018-05-10 | 2023-10-16 | アムジエン・インコーポレーテツド | KRAS G12C inhibitors for the treatment of cancer |
EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
CN112513031A (en) | 2018-06-04 | 2021-03-16 | 阿普罗斯治疗公司 | Acid group containing pyrimidine compounds useful for the treatment of diseases associated with the modulation of TLR7 |
AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
US20220047716A1 (en) | 2018-09-17 | 2022-02-17 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
EP3883565A1 (en) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US20220056015A1 (en) | 2018-12-20 | 2022-02-24 | Amgen Inc. | Kif18a inhibitors |
US11236069B2 (en) | 2018-12-20 | 2022-02-01 | Amgen Inc. | KIF18A inhibitors |
WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
ES2953821T3 (en) | 2018-12-20 | 2023-11-16 | Amgen Inc | KIF18A inhibitors |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
EP3931195A1 (en) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
CN114391012A (en) | 2019-08-02 | 2022-04-22 | 美国安进公司 | Pyridine derivatives as KIF18A inhibitors |
JP2022542394A (en) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Heteroarylamides useful as KIF18A inhibitors |
WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
CA3146693A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
CA3152674A1 (en) | 2019-08-31 | 2021-03-04 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivatives for fgfr inhibitor and preparation method thereof |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
CN115873020A (en) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | RAS inhibitors |
CN114867735A (en) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | RAS inhibitors |
EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
KR20220100903A (en) | 2019-11-08 | 2022-07-18 | 레볼루션 메디슨즈, 인크. | Bicyclic heteroaryl compounds and uses thereof |
IL292315A (en) | 2019-11-14 | 2022-06-01 | Amgen Inc | Improved synthesis of kras g12c inhibitor compound |
AU2020383535A1 (en) | 2019-11-14 | 2022-05-05 | Amgen Inc. | Improved synthesis of KRAS G12C inhibitor compound |
EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
TW202140011A (en) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2 inhibitor dosing and methods of treating cancer |
WO2021178597A1 (en) | 2020-03-03 | 2021-09-10 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
PE20231207A1 (en) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT |
CN117396472A (en) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | SOS1 inhibitors and uses thereof |
AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
AR125782A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
TW202408589A (en) | 2022-06-30 | 2024-03-01 | 美商舒卓生物製藥公司 | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti‑ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3266990A (en) | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
US3870725A (en) | 1971-03-30 | 1975-03-11 | Lilly Industries Ltd | Nitrothiazole derivatives |
JPS542327A (en) | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2160201B (en) | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
DE68917485T2 (en) | 1988-01-23 | 1995-02-09 | Kyowa Hakko Kogyo Kk | Pyridazinone derivatives and pharmaceutical preparations containing them. |
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
ATE121735T1 (en) | 1991-02-20 | 1995-05-15 | Pfizer | 2,4-DIAMINOQUINAZOLINE DERIVATIVES TO INCREASE ANTITUMOR EFFECT. |
IL101291A0 (en) | 1991-03-22 | 1992-11-15 | Nippon Soda Co | 2-pyridine derivatives,their preparation and their use as fungicides |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
DE4208254A1 (en) | 1992-03-14 | 1993-09-16 | Hoechst Ag | SUBSTITUTED PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL AND FUNGICIDE |
US5270466A (en) | 1992-06-11 | 1993-12-14 | American Cyanamid Company | Substituted quinazoline fungicidal agents |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
WO1995006648A1 (en) | 1993-09-03 | 1995-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivative |
JPH07126165A (en) | 1993-10-29 | 1995-05-16 | Masao Oguro | Therapeutic agent for tumor |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
CA2183655C (en) | 1994-02-23 | 2001-03-06 | Lee D. Arnold | 4-polycyclic amino-substituted quinazoline derivatives |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
DK0682027T3 (en) | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidine derivatives with antiproliferative action |
DE19503151A1 (en) | 1995-02-01 | 1996-08-08 | Thomae Gmbh Dr K | New phenylamino substd. pyrimido-pyrimidine derivs. |
TW414798B (en) | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (en) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
AU5108196A (en) | 1995-03-20 | 1996-10-08 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
DE69609602T2 (en) | 1995-04-03 | 2001-04-12 | Novartis Ag | PYRAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
DE69613367T2 (en) | 1995-04-27 | 2002-04-18 | Astrazeneca Ab | CHINAZOLIN DERIVATIVES |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
ATE182148T1 (en) | 1995-05-12 | 1999-07-15 | Neurogen Corp | NEW DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1-SPECIFIC LIGANDS |
TW334434B (en) | 1995-05-16 | 1998-06-21 | Kanebo Ltd | Novel quinazoline compound and anti-tumor agent |
US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
PT831829E (en) | 1995-06-07 | 2003-12-31 | Pfizer | PYRIMIDINE DERIVATIVES FROM HETEROCYCLICS OF FUSED RINGS |
WO1996040648A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
SK398A3 (en) | 1995-07-06 | 1998-07-08 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
AR004010A1 (en) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | HETERO CYCLIC COMPOUNDS |
UA57002C2 (en) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment |
EP0904269B1 (en) | 1995-10-30 | 2002-01-23 | Merck Frosst Canada & Co. | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
WO1997017329A1 (en) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
EA000072B1 (en) | 1995-11-14 | 1998-06-25 | Фармация Энд Апджон С.П.А. | Aryl and heteroaryl purine compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (en) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo (2,3-d) pyrimides and their use. |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
EP0880508B1 (en) * | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
ATE211134T1 (en) | 1996-03-05 | 2002-01-15 | 4-ANILINOQUINAZOLINE DERIVATIVES | |
DE19608588A1 (en) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation |
DE19629652A1 (en) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
DE19608631A1 (en) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
DE19608653A1 (en) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
AU5533996A (en) | 1996-04-04 | 1997-10-29 | University Of Nebraska Board Of Regents | Synthetic triple helix-forming compounds |
RO121900B1 (en) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinazes, pharmaceutical composition containing the same and use thereof |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
DE19614718A1 (en) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituted pyridines / pyrimidines, processes for their preparation and their use as pesticides |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
GB9613021D0 (en) | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
AR007857A1 (en) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | HETERO-CYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS, THYROSINE KINASE, THEIR PREPARATION METHODS, INTERMEDIARY USE IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EA199900021A1 (en) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEINTHYROSINKINASE INHIBITORS |
WO1998007726A1 (en) | 1996-08-23 | 1998-02-26 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
IL128994A (en) | 1996-09-25 | 2004-12-15 | Zeneca Ltd | Quinoline and naphthyridine derivatives and salts thereof, processes for their preparation, pharmaceutical compositions containing them and use thereof as medicaments |
EP0882717B1 (en) | 1996-10-01 | 2010-09-08 | Kyowa Hakko Kirin Co., Ltd. | Nitrogenous heterocyclic compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
KR20000057228A (en) | 1996-11-27 | 2000-09-15 | 디. 제이. 우드, 스피겔 알렌 제이 | Fused bicyclic pyrimidine derivatives |
CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
AR016817A1 (en) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
DE69838172T2 (en) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER |
DE19742379C1 (en) * | 1997-09-25 | 1999-02-11 | Siemens Ag | Ultrasonic therapy device operating method |
KR100860295B1 (en) | 1998-10-08 | 2008-09-25 | 아스트라제네카 아베 | Quinazoline derivatives |
ATE482946T1 (en) * | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATE PRODUCTS THEREFOR |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
MXPA02004366A (en) | 1999-11-05 | 2002-11-07 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors. |
AU2001235804A1 (en) | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
ES2267748T3 (en) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | QUINAZOLINE COMPOUNDS. |
WO2002012226A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
EP1311500A2 (en) | 2000-08-09 | 2003-05-21 | AstraZeneca AB | Indole, azaindole and indazole derivatives having vegf inhibiting activity |
ES2317923T3 (en) | 2000-08-09 | 2009-05-01 | Astrazeneca Ab | CINOLINE COMPOUNDS. |
GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
EP1474420B1 (en) | 2002-02-01 | 2012-03-14 | AstraZeneca AB | Quinazoline compounds |
GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
KR20050056190A (en) | 2002-08-09 | 2005-06-14 | 아스트라제네카 아베 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
DK1592423T3 (en) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU and / or CPT-11 |
-
2000
- 2000-11-01 MX MXPA02004366A patent/MXPA02004366A/en active IP Right Grant
- 2000-11-01 JP JP2001534802A patent/JP3522727B2/en not_active Expired - Lifetime
- 2000-11-01 NZ NZ518028A patent/NZ518028A/en not_active IP Right Cessation
- 2000-11-01 AU AU12886/01A patent/AU769222B2/en active Active
- 2000-11-01 KR KR1020077022543A patent/KR100881104B1/en active IP Right Grant
- 2000-11-01 UA UA2002064594A patent/UA72946C2/en unknown
- 2000-11-01 SK SK612-2002A patent/SK287401B6/en not_active IP Right Cessation
- 2000-11-01 CN CNA2008100037759A patent/CN101219145A/en active Pending
- 2000-11-01 KR KR1020087004070A patent/KR100881105B1/en active IP Right Grant
- 2000-11-01 AT AT06004921T patent/ATE398120T1/en active
- 2000-11-01 ES ES06004921T patent/ES2306306T3/en not_active Expired - Lifetime
- 2000-11-01 US US10/129,336 patent/US7173038B1/en not_active Expired - Lifetime
- 2000-11-01 DK DK00974667T patent/DK1244647T3/en active
- 2000-11-01 HU HU0203453A patent/HU229414B1/en active Protection Beyond IP Right Term
- 2000-11-01 EP EP06004921A patent/EP1676845B1/en not_active Expired - Lifetime
- 2000-11-01 PL PL355942A patent/PL203782B1/en not_active IP Right Cessation
- 2000-11-01 RU RU2002114809/04A patent/RU2291868C2/en active Protection Beyond IP Right Term
- 2000-11-01 PT PT00974667T patent/PT1244647E/en unknown
- 2000-11-01 AT AT00974667T patent/ATE330954T1/en active
- 2000-11-01 PT PT06004921T patent/PT1676845E/en unknown
- 2000-11-01 EE EEP200200237A patent/EE05330B1/en active Protection Beyond IP Right Term
- 2000-11-01 IL IL14903400A patent/IL149034A0/en unknown
- 2000-11-01 EP EP00974667A patent/EP1244647B1/en not_active Expired - Lifetime
- 2000-11-01 BR BRPI0015203A patent/BRPI0015203B8/en unknown
- 2000-11-01 CZ CZ20021526A patent/CZ301689B6/en unknown
- 2000-11-01 CA CA2389767A patent/CA2389767C/en not_active Expired - Lifetime
- 2000-11-01 DE DE60039206T patent/DE60039206D1/en not_active Expired - Lifetime
- 2000-11-01 SI SI200030877T patent/SI1244647T1/en unknown
- 2000-11-01 ES ES00974667T patent/ES2265998T3/en not_active Expired - Lifetime
- 2000-11-01 SI SI200031001T patent/SI1676845T1/en unknown
- 2000-11-01 DE DE60029007T patent/DE60029007T2/en not_active Expired - Lifetime
- 2000-11-01 BR BR0015203-0A patent/BR0015203A/en not_active IP Right Cessation
- 2000-11-01 KR KR1020027005814A patent/KR100849151B1/en active Protection Beyond IP Right Term
- 2000-11-01 WO PCT/GB2000/004181 patent/WO2001032651A1/en active IP Right Grant
- 2000-11-01 DK DK06004921T patent/DK1676845T3/en active
- 2000-11-01 CN CNB008153108A patent/CN100376567C/en not_active Expired - Lifetime
- 2000-11-03 AR ARP000105821A patent/AR033499A1/en active IP Right Grant
- 2000-11-29 TW TW089125343A patent/TWI287540B/en active
-
2002
- 2002-04-08 IL IL149034A patent/IL149034A/en active Protection Beyond IP Right Term
- 2002-04-09 ZA ZA200202775A patent/ZA200202775B/en unknown
- 2002-04-09 IS IS6335A patent/IS2284B/en unknown
- 2002-04-26 BG BG106659A patent/BG65861B1/en unknown
- 2002-05-03 NO NO20022139A patent/NO322298B1/en not_active IP Right Cessation
-
2003
- 2003-03-07 HK HK03101686.4A patent/HK1049664B/en not_active IP Right Cessation
-
2006
- 2006-09-21 CY CY20061101355T patent/CY1106166T1/en unknown
- 2006-12-08 HK HK06113553A patent/HK1092804A1/en unknown
- 2006-12-21 US US11/642,979 patent/US20070265286A1/en not_active Abandoned
-
2007
- 2007-09-04 IS IS8673A patent/IS2556B/en unknown
-
2008
- 2008-08-12 CY CY20081100853T patent/CY1108256T1/en unknown
-
2010
- 2010-04-15 US US12/761,105 patent/US8642608B2/en not_active Expired - Lifetime
-
2012
- 2012-08-07 LU LU92057C patent/LU92057I2/en unknown
- 2012-08-07 NO NO2012014C patent/NO2012014I1/en unknown
- 2012-08-09 BE BE2012C036C patent/BE2012C036I2/fr unknown
- 2012-08-09 FR FR12C0048C patent/FR12C0048I2/en active Active
- 2012-08-14 CY CY2012026C patent/CY2012026I1/en unknown
-
2014
- 2014-01-03 US US14/146,954 patent/US9040548B2/en not_active Expired - Fee Related
-
2015
- 2015-05-22 US US14/719,779 patent/US20160130249A1/en not_active Abandoned
-
2017
- 2017-06-19 US US15/626,576 patent/US20180099946A1/en not_active Abandoned
- 2017-12-28 US US15/856,235 patent/US10457664B2/en not_active Expired - Fee Related
-
2019
- 2019-09-25 US US16/582,469 patent/US20200262811A1/en not_active Abandoned
-
2021
- 2021-01-15 US US17/150,856 patent/US20210276972A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR12C0048I2 (en) | QUINAZOLINE DERIVATIVES USED AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS | |
FR22C1036I1 (en) | PYRIMIDINE DERIVATIVES AS HIV INHIBITOR | |
FR15C0086I2 (en) | HYDROXAMATE DERIVATIVES AS DESACETYLASE INHIBITORS | |
FR20C1039I2 (en) | DERIVATIVES OF UK-2A | |
DZ3425A1 (en) | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | |
FR14C0055I2 (en) | SUBSTITUTED CYANOQUINOLINES 3 AS PROTEIN TYROSINE KINASE INHIBITORS | |
MA27012A1 (en) | DIHYDRO-BENZO [B] [1,4] DERIVATIVES DIAZEPIN-2-ONE AS AN AGONISTS II OF MGLUR2 | |
MA26972A1 (en) | TETRALONE DERIVATIVES AS ANTI-TUMOR AGENTS | |
FR14C0024I2 (en) | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | |
MA26837A1 (en) | HETEROALKY-LAMINO BICYCLIC NITROGEN HETEROCYCLES SUBSTITUTED AS P38 PROTEIN KINASE INHIBITORS. | |
FR07C0057I2 (en) | PLEUROMUTILINE DERIVATIVES USED AS ANTIMICROBIAL AGENTS | |
FR08C0007I2 (en) | TRIAZOLYLTROPANE DERIVATIVES USED AS CCR5 MODULATORS | |
MA26994A1 (en) | QUINAZOLINES AS INHIBITORS OF MMP-13 | |
MA26932A1 (en) | DERIVATIVES OF IMIDAZOLE. | |
EP1385862A4 (en) | Vascular endothelial growth factor 2 | |
MA26836A1 (en) | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS P38 PROTEIN KINASE INHIBITORS. | |
MA26816A1 (en) | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | |
DZ3439A1 (en) | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | |
MA27230A1 (en) | AMINOINDAZOLES DERIVATIVES AS PROTEIN KINASE INHIBITORS | |
MA25433A1 (en) | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | |
MA26782A1 (en) | PYRAZOLOBENZODIAZEPINES AS CDK2 INHIBITORS. | |
MA25493A1 (en) | DERIVATIVES OF 3 (5) -AMINO-PYRAZOLE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-TUMOR AGENTS. | |
DZ3506A1 (en) | PYRROLE DERIVATIVES FOR USE AS PHARMACEUTICAL AGENTS | |
FR11C0042I2 (en) | COMPOUNDS CONTAINING LACTAME AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS | |
EE200200673A (en) | Quinazoline derivatives for the treatment of tumors |